Drupal.behaviors.print = function(context) {window.print();window.close();}>
UNC Teams Uncovers How HCV Uses miR-122 to Survive
January 05, 2012
UNC Teams Uncovers How HCV Uses miR-122 to Survive
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Santaris Nears End of Phase II Trial of miRNA HCV Rx, Seeks Partnership Since GSK Opted Out
September 15, 2011 / Gene Silencing News
EPO to Hear Mirrx Request for Resumption of Patent Proceedings Covering miRNA Rx Technology
January 20, 2011 / Gene Silencing News
Santaris Sues Mirrx Founder Over Blockmir Technology
May 6, 2010 / Gene Silencing News
Santaris Pharma to Begin Phase II Development of miRNA-Targeting HCV Drug
September 23, 2010 / Gene Silencing News
Regulus, GSK Ink Second miRNA Rx Collaboration
February 25, 2010 / Gene Silencing News